Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | TXK | P42681 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045937 | 0.91 | USP30 (0.41) | USP30KRASBTKEGFRPAX8 | |
| SCHEMBL20045472 | 0.84 | USP30 (0.45) | USP30KRASBTKHSD17B3 | |
| SCHEMBL20046113 | 0.83 | TDP2 (0.42) | KRASBTKLIPG | |
| SCHEMBL20045471 | 0.82 | TDP2 (0.42) | KRASBTKEGFR | |
| SCHEMBL20045939 | 0.80 | BTK (0.36) | KRASBTKHRH3 | |
| SCHEMBL20132849 | 0.79 | ACHE (0.42) | KRASBTKEGFR | |
| SCHEMBL20046107 | 0.79 | TDP2 (0.38) | KRASBTKEGFRITK | |
| SCHEMBL20046111 | 0.78 | MAP3K5 (0.36) | KRASBTKEGFR | |
| SCHEMBL20045476 | 0.78 | JAK3 (0.34) | KRASBTKEGFR | |
| SCHEMBL20045454 | 0.78 | KRAS (0.51) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | USP30 1696/4885KRAS 1/4885BTK 758/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | USP30 1574/4885KRAS 1/4885BTK 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.